|
1.Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Supportive Care in Cancer. 2005;13:219-227.
2.Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187-198.
3.Hesketh PJ. Chemotherapy-induced nausea and vomiting. The New England Journal of Medicine. 2008;358:2482-2494.
4.Hamada S, Hinotsu S, Hori K, et al. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study. Supportive Care in Cancer. 2011;20:813-820.
5.Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supportive Cancer Therapy. 2005;2:181-187.
6.Tina Shih Y-C, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110:678-685.
7.Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Annals of Oncology. 2004;15:526-536.
8.Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Supportive Care in Cancer. 2010;19:131-140.
9.Craver C, Gayle J, Balu S, et al. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ. 2011;14:87-98.
10.Haiderali A, Menditto L, Good M, et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Supportive Care in Cancer. 2011;19:843-851.
11.Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology. 2003;21:4112-4119.
12.Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
13.Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Annals of Oncology. 2006;17:1000-1006.
14.Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology. 2006;24:2932-2947.
15.Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of Oncology. 2010;21 Suppl 5:v232-243.
16.Ettinger D, Armstrong DK, Barbour S, et al. NCCN Clinical Practice Guidelines in Oncology: Antiemesis Journal of the National Comprehensive Cancer Network. 2011;V1.2012:1-43.
17.Accounting Office of Bureau of National Health Insurance. Year 2011 National Health Insurance Annual Statistics Report. Department of Health, Executive Yuan, Taiwan. 2011; Available at: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=661&WD_ID=689&webdata_id=4004.[Date accessed: April 9, 2012]
18.Lordick F, Ehlken B, Ihbe-Heffinger A, et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007;43:299-307.
19.Moore S, Tumeh J, Wojtanowski S, et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value in Health. 2007;10:23-31.
20.Annemans L, Strens D, Lox E, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Supportive Care in Cancer. 2008;16:905-915.
21.Chan A, Lopes G, Burke T, et al. Aprepitant for patients receiving highly emetogenic chemotherapy: an economic analysis for Singapore. Value in Health Regional Issues. 2012;1:66-74.
22.Common Drug Review. Aprepitant (EmendTM - Merck Frosst Canada Ltd.), Indication - Chemotherapy-induced Nausea and Vomiting: Overview of CDR Clinical and Pharmacoeconomic Reports [May 2008]: Ottawa: Canadian Agency for Drugs and Technologies in Health;2008.
23.Pharmaceutical Benefits Advisory Committe. PBAC (Australia) Public Summary Document: Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend®. Department of Health and Ageing, Australian Government. March, 2006; Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-aprepitant-mar06. [Date accessed: April 9 2012]
24.Pharmaceutical Benefits Advisory Committe. PBAC (Australia) Public Summary Document for Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend®. Department of Health and Ageing, Australia Government. November, 2009; Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-Aprepitant-nov09. [Date accessed: April 9, 2012]
25.Pharmaceutical Benefits Advisory Committe. PBAC (Australia) Public Summary Document: Aprepitant, pack containing 1 capsule 125 mg and 2 capsules 80 mg, Emend®. Department of Health and Ageing, Australia Government. March, 2010; Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-aprepitant-mar10. [Date accessed: April 9, 2012]
26.Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Supportive Care in Cancer. 2007;15:497-503.
27.Bloechl-Daum B. Delayed Nausea and Vomiting Continue to Reduce Patients'' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment. Journal of Clinical Oncology. 2006;24:4472-4478.
28.Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology. 2011;22:30-38.
29.DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg''s cancer : principles & practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
30.Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chemical Reviews. 2009;109:3158-3199.
31.Hesketh PJ, Van Belleb S, Aaproc M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. European Journal of Cancer. 2003;39:1074-1080.
32.Pathophysiology and prediction of chemotherapy-induced nausea and vomiting. UpToDate; 2011. Available at: www.uptodate.com. [Date accessed: May 20, 2011]
33.Rojas C, Slusher B. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1-7.
34.Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191-196.
35.Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2011;29:4189-4198.
36.Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. The Journal of Supportive Oncology. 2007;5:374-380.
37.Dranitsaris G, Joy A, Young S, et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool - II. Delayed nausea and vomiting. Journal of Supportive Oncology. 2009;7:W1-W8.
38.Kaasa S, Kvaloy S, Dicato MA, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer. 1990;26:311-314.
39.Jordan K, Hinke A, Grothey A, et al. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Supportive Care in Cancer. 2005;13:26-31.
40.Aapro M, Johnson J. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology. 2005;51:287-296.
41.Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Supportive Care in Cancer. 2007;15:1023-1033.
42.Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996;32A:807-813.
43.Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. Journal of Clinical Oncology. 1999;17:2971-2974.
44.Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supportive Care in Cancer. 2005;13:85-96.
45.Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. Journal of Clinical Oncology. 2005;23:1289-1294.
46.Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos. 2003;31(6):785-791.
47.Bergstrom M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004;55:1007-1012.
48.Merk Sharp & Dohme Corp. Prescribing Information for EMEND (aprepitant) Capsules. 2012. Available at: http://www.emend.com/aprepitant/emend/consumer/product_information/pi/index.jsp. [Date accessed: June 18, 2012]
49.Merk Sharp & Dohme Corp. Prescribing Information of EMEND (fosaprepitant dimeglumine) for Injection. 2011. Available at: http://www.emend.com/aprepitant/emend/consumer/product_information/pi/index.jsp. [Date accessed: June 18, 2012]
50.Weinstein MC, Stason WB. Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine. 1977;296:716-721.
51.Bootman J, Townsend R, McGhan W. Introduction to pharmacoeconomics: Principles of pharmacoeconomics. 2nd ed. Cincinnati, OH: Harvey Whitney Books; 1996:1-18.
52.Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. USA: Oxfor University Press; 1996.
53.Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3 ed. USA: Oxford University Press; 2005.
54.Edejer TT-T, World Health Organization. Making choices in health : WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
55.Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edition. Ottawa. 2006.
56.Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee V 4.3. Department of Health and Ageing, Australia; 2008.
57.Wonderling D, Sawyer L, Fenu E, et al. National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence. Annals of Internal Medicine. 2011;154:758-765.
58.Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Medical Care. 2009;47:S28-S32.
59.Farnham P, Haddix A. Study design. In: Haddix A, Teutsch S, Shaffer P, Duñet D, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press; 2003:11-27.
60.Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. 1st ed. USA: Oxford University Press; 2006.
61.Sun X, Faunce T. Decision-analytical modelling in health-care economic evaluations. The European Journal of Health economics. 2008;9:313-323.
62.Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics. 2006;24:355-371.
63.Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:2290-2300.
64.de Wit R. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Journal of Clinical Oncology. 2003;21:4105-4111.
65.Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41:1278-1285.
66.de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403-410.
67.Wu CE, Liaw CC. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Supportive Care in Cancer. 2011. DOI 10.1007/s00520-011-1345-z.
68.Chirsp P. Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2007;2:15-30.
69.Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548-1555.
70.Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.Supportive Care in Cancer. 2010;18:423-431.
71.Scottish Medicines Consortium. Aprepitant (Emend®) Summary of Advice No.132/04, 08 November 2004. Available at:http://www.scottishmedicines.org.uk/files/aprepitant__Emend_.pdf. [Date accessed: June 20, 2012]
72.Regional Drug and Therapeutics Centre (Newcastle). The use of aprepitant for the prevention of chemotherapy induced nausea and vomiting. National Health Service, United Kingdom.2009.Available at:http://www.nyrdtc.nhs.uk/. [Date accessed: June 20, 2012]
73.Scottish Medicines Consortium. Aprepitant 125mg, 80mg capsules (Emend®) Merck Sharp and Dohme Ltd. Advice No. 242/06, 07 October 2011. New indication:prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Available at: http://www.scottishmedicines.org.uk/files/aprepitant__Emend_.pdf.[Date accessed: June 20, 2012]
74.Bureau of National Health Insurance. Pharmaceutical Benefit Scheme for National Health Insurance. Department of Health, Executive Yuan, Taiwan. 2012. Available at: http://www.nhi.gov.tw/. [Date accessed: June 20, 2012]
75.XE: The World''s Favourite Currency Site. 2012. Available at: http://www.xe.com/. [Date accessed: June 20, 2012]
76.Grunberg SM, Weeks J, Magnan WF, et al. Determination of utility scores for control of chemotherapy-induced nausea or vomiting—CALGB 3. The Journal of Supportive Oncology. 2009;7:W17-W22.
77.Grunberg SM, Boutin N, Ireland A, et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Supportive Care in Cancer. 1996;4:435-439.
78.Borjeson S, Hursti TJ, Peterson C, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale.Cancer Nurs. 1997;20:260-266.
79.Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87:118-128.
80.Bureau of National Health Insurance Reference List for Drugs (RLD). Department of Health, Executive Yuan, Taiwan. 2011. Available at: http://www.nhi.gov.tw/.[Date accessed: June 20, 2012]
81.Bureau of National Health Insurance fee schedule for medical services. Department of Health, Executive Yuan, Taiwan. 2011. Available at: http://www.nhi.gov.tw/. [Date accessed: June 20, 2012]
82.Directorate General of Budget, Accounting and Statistics. National Account Statistics: Principal Figures - Annual. Executive Yuan, Taiwan. 2012; Available at: http://eng.stat.gov.tw. [Accessed June 13, 2012].
83.Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods. 2007;39:175-191.
84.Warr DG. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy. Journal of Clinical Oncology. 2004;23(12):2822-2830.
85.Jin Y, Wu X, Guan Y, et al. Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Supportive Care in Cancer. 2011;20:1815-22.
86.Hesketh PJ, Younger J, Sanz-Altamira P, et al.Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Supportive Care in Cancer. 2008.17:1065-1070.
87.Tagashira H, Matsuhisa T, Oze I, et al.[Efficacy and safety of aprepitant in patients with breast cancer]. Gan to kagaku ryoho. Cancer & Chemotherapy. 2011;38:1307-1311.
88.Yakabe T, Mochinaga S, Fujito H, et al.[Antiemetic effect of aprepitant in cancer patients receiving Cisplatin regimen].Gan to kagaku ryoho.Cancer & Chemotherapy. 2012;39:69-73.
89.Fang ZW, Zhai SD.[A meta-analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting]. Beijing Da Xue Xue Bao. 2010;42:756-763.
90.Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Supportive Care in Cancer. 2009;1:589-594.
91.Avritscher EB, Shih YC, Sun CC, et al. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. The Journal of Supportive Oncology. 2010;8:242-251.
92.World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE): Cost Effectiveness Threshold. 2012; Available at: http://www.who.int/choice/costs/CER_thresholds/en/index.html.[Date accessed: June 4, 2012]
93.Bureau of National Health Insurance. Guidelines of price adjustment for National Health Insurance reimbursed drugs 2008; Available at: http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=295&WD_ID=295&webdata_id=2444.[Date accessed: June 21, 2012]
94.del Giglio A, Soares HP, Caparroz C, et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer. 2000;89:2301-2308.
|